ESTRO 38 Abstract book

S8 ESTRO 38

omitted in patients with a PET negative result after chemotherapy. The final results from these studies showed, that patients who received chemotherapy only due to a negative PET had a worse PFS. Therefore the combined modality approach remains the standard of care for patients in early stages. SP-0022 State of the art for indolent lymphoma J. Yahalom 1 1 Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, USA SP-0023 Aggressive Lymphoma (DLBCL); when does addition of RT make a difference? G. Mikhaeel 1,2 1 Guy's and St.Thomas' NHS Foundation Trust, Department of Clinical Oncology, London, United Kingdom; 2 King's College, Division of Cancer Studies, London, United Kingdom Abstract not received

reactivation, which can be avoided with antiviral prophylaxis. People living with HIV are at high risk of cancer, and especially lung cancer. There are specific guidelines for the management of patients with HIV and cancer (2). Diabetes mellitus is associated with higher mortality in patients with lung cancer, increasing the risk of cardiovascular and infectious events. Complications of diabetes, such as chronic renal insufficiency and peripheral neuropathy can interfere with the treatment of lung cancer. Frequent need for corticosteroids during chemotherapy requires closed monitoring of glycaemia. Adjuvant durvalumab after chemoradiotherapy has been shown to improve overall survival in stage III NSCLC. Autoimmune diseases or diseases requiring immunosuppressive therapy (including corticosteroids > 10 mg/day) and ILD can preclude their use. The comorbidity burden of patients with stage III NSCLC is high, with a variety of diseases and a frequent association of several comorbidities. A thorough work-up of patients exploring these comorbidities is needed before treatment decision, which should be best taken after treatment optimization of all comorbidities within a multidisciplinary setting References : 1.Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. janv 2007;43(1):14-34. 2. Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, et al. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. août 2018;16(8):986-1017. SP-0020 Role of patient reported outcome in patients follow-up L.Yolande 1 1 Ghent University Hospital and Ghent University, Department of Radiation Oncology, Ghent, Belgium SP-0021 The role of radiotherapy in Hodgkin Lymphoma - results from the German Hodgkin Study Group (GHSG) H.T. Eich 1 1 University of Münster, Department of Radiation Oncology, Münster, Germany Abstract text Thomas Hodgkin was the first who described the disease in 1832 in his publication entitled "On some morbid appearances of the absorbent gland and spleen". Nowadays Hodgkin's Lymphoma has rendered to one of the best curable malignancies. The treatment of patients in early favorable and early unfavorable consists of chemotherapy followed by Involved-Site Radiotherapy (RT). Patients in advanced stages are treated with intensified chemotherapy and PET-guided radiotherapy. Due to optimized chemotherapy regimen and modern RT Overall Survival (OS) is up to 96,8% for patients in early favorable stages, 94,5% in early unfavorable stages and 95,3% in advanced stages. The development of RT within the past decades is remarkable. Field designs and radiation techniques changed dramatically throughout the years. In early favorable stages RT-dose decreased to 20 Gy Involved-Site RT and in early unfavorable stages the dose is 30 Gy. The recently completed trials conducted by the EORTC and the GHSG tested whether RT can be Abstract not received Symposium: Combined modality treatment vs chemotherapy alone in lymphoma patients?

Abstract not received

SP-0024 Aggressive Lymphoma (DLBCL) - when does addition of RT doesn’t make a difference? U.Vitolo 1 University of Turin, Department of Oncology and Hematology Turin,Italia

Abstract not received

Symposium: Image guided adaptive brachytherapy (IGABT) for primary vaginal cancer in Europe and North America

SP-0025 Evidence for image guided adaptive brachytherapy in primary vaginal cancer H. Westerveld 1 1 Amsterdam UMC AMC, Radiation Oncology, Amsterdam, The Netherlands Abstract text Primary vaginal cancer (PVC) is a very rare disease. In most cases, definitive radiotherapy (external beam radiotherapy (EBRT) followed by a brachytherapy (BT) boost) combined with chemotherapy is the treatment of choice. PET (CT), ultrasound and MRI can all play a role in the diagnostic work-up, response assessment and planning of the EBRT and BT in PVC cases. However, due to its superiority of soft tissue contrast and the possibility of functional imaging, MRI is the best image modality in the diagnostic process and for delineation of the target at time of treatment. Due to its rarity, only limited data are available about the use of image guided adaptive brachytherapy (IGABT) in primary vaginal cancer. Most studies include small retrospective series of patients that have been included over a long period of time. The studies can be categorized in two groups with regard to the treatment technique. One group includes older studies where patients have been treated with 2D radiograph- based BT. The other group includes more recent monocenter studies where patients have been treated according to a 3D BT target concept adopted from GEC- ESTRO recommendations for cervical cancer. Although these 3D studies are very small, results are promising showing better local control without additional morbidity. Recently, a retrospective multicenter study was conducted to assess the outcome of patients treated for PVC with IGABT, defined by the use of MRI at time of brachytherapy. At a median follow-up of 29 months (range 3-167), the 3 years local control rate was 82%. Improved local control was found in patients with T2-4 tumor if >80